+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide



The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide



British Journal of Ophthalmology 90(11): 1344-1349



Off-label intravitreal injections of bevacizumab (Avastin) have been given for the treatment of neovascular and exudative ocular diseases since May 2005. Since then, the use of intravitreal bevacizumab has spread worldwide, but the drug-related adverse events associated with its use have been reported only in a few retrospective reviews. The International Intravitreal Bevacizumab Safety Survey was initiated to gather timely information regarding adverse events from doctors around the world via the internet. An internet-based survey was designed to identify adverse events associated with intravitreal bevacizumab treatment. The survey web address was disseminated to the international vitreoretinal community via email. Rates of adverse events were calculated from participant responses. 70 centres from 12 countries reported on 7113 injections given to 5228 patients. Doctor-reported adverse events included corneal abrasion, lens injury, endophthalmitis, retinal detachment, inflammation or uveitis, cataract progression, acute vision loss, central retinal artery occlusion, subretinal haemorrhage, retinal pigment epithelium tears, blood pressure elevation, transient ischaemic attack, cerebrovascular accident and death. None of the adverse event rates exceeded 0.21%. Intravitreal bevacizumab is being used globally for ocular diseases. Self-reporting of adverse events after intravitreal bevacizumab injections did not show an increased rate of potential drug-related ocular or systemic events. These short-term results suggest that intravitreal bevacizumab seems to be safe.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012892002

Download citation: RISBibTeXText

PMID: 16854824

DOI: 10.1136/bjo.2006.099598


Related references

The international intravitreal bevacizumab safety survey. British Journal of Ophthalmology 90(11): 1440-1441, 2006

Impact of the Global Food Safety Initiative on Food Safety Worldwide: Statistical Analysis of a Survey of International Food Processors. Journal of Food Protection 80(10): 1613-1622, 2017

Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions. European Journal of Clinical Pharmacology 70(12): 1505-1512, 2014

Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie 45(3): 231-238, 2010

The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Safety 19(1): 1-10, 1998

Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 31(1): 111-118, 2011

A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. Clinical Ophthalmology 9: 1759-1766, 2015

Safety of intravitreal bevacizumab in the developing rabbit retina. Retina 31(9): 1885-1895, 2011

Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26(8): 882-888, 2006

Global index of safety A new instrument to assess drug safety Application to a prospective pharmacoepidemiological study. European Journal of Neurology 7(Suppl. 3): 140, 2000

Global index of safety (GIS): a new instrument to assess drug safety. Journal of Clinical Epidemiology 54(11): 1120-1125, 2001

Safety of intravitreal injections: Non-inferiority of bevacizumab compared with ranibizumab. International Journal of Clinical Pharmacology and Therapeutics 57(1): 41-42, 2019

Measuring safety culture: Application of the Hospital Survey on Patient Safety Culture to radiation therapy departments worldwide. Practical Radiation Oncology 8(1): E17, 2018

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmologica 88(2): E3; Author Reply E4, 2010

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmologica 86(7): 800-805, 2008